A year ago, Wegovy became the first GLP-1 drug ever approved to treat a form of liver disease. Metabolic dysfunction-associated steatohepatitis — MASH, the condition doctors used to call NASH — had never had an FDA-approved pharmacologic treatment for patients with real fibrosis until semaglutide got there in August 2025. Now that the dust has settled, updated clinical practice guidance has landed, and industry analysts have had a full year of prescribing data to look at, it’s worth asking the question that matters more than the approval headline itself: is it actually changing how fatty liver disease gets treated?
A Quick Refresher on What MASH Is
MASH is the aggressive cousin of simple fatty liver. Where garden-variety metabolic dysfunction-associated steatotic liver disease (MASLD) is fat accumulation in the liver with little immediate danger, MASH adds inflammation and active liver cell injury — and left untreated, a meaningful share of MASH patients progress to fibrosis, cirrhosis, and liver failure. Current prevalence estimates put MASH at somewhere between 1% and 6% of the general U.S. population, but that number climbs sharply in people with type 2 diabetes, where roughly seven in ten have some form of MASLD and about half of those have progressed to MASH. Projections suggest MASH cases could reach 27 million in the U.S. by 2030, tracking almost exactly with the obesity and diabetes trends the GLP-1 class was originally built to treat.
What the ESSENCE Trial Actually Showed
The FDA’s accelerated approval rested on interim results from ESSENCE, a Phase 3 trial that enrolled roughly 800 adults with biopsy-confirmed MASH and moderate-to-advanced fibrosis (stage F2 or F3). After 72 weeks on 2.4 mg weekly semaglutide, 62.9% of patients achieved MASH resolution without their fibrosis getting worse, compared to about 34% on placebo — and 37% saw measurable fibrosis improvement, against 22% on placebo. Those are histologic endpoints, meaning they were confirmed on paired liver biopsies before and after treatment, not just blood markers or imaging — a genuinely hard bar to clear in liver disease trials, where placebo response rates are notoriously stubborn.
Because this was an accelerated approval, it comes with a catch: Novo Nordisk still owes the FDA confirmatory evidence that the histologic improvements translate into fewer real clinical outcomes — cirrhosis, liver transplants, liver-related deaths. Part 2 of ESSENCE is already running, tracking patients out to 240 weeks (roughly 4.6 years) to answer exactly that question. Until those results land, MASH joins a growing list of GLP-1 indications approved on strong surrogate endpoints with the long-term outcomes data still pending.
What Changed in the Last Year
The most concrete development since the original approval isn’t a new trial — it’s updated clinical guidance. In November 2025, the American Association for the Study of Liver Diseases (AASLD) issued practice guidance specifically addressing how semaglutide should be used for MASH, giving hepatologists and primary care providers a clearer framework for who’s actually a candidate, how to sequence it against other interventions like weight loss counseling and vitamin E, and how to monitor response. That guidance mattered more for real-world adoption than the approval itself — a drug doesn’t get used broadly just because the FDA cleared it; it gets used once specialty societies tell frontline clinicians how to fit it into an actual treatment plan.
By January 2026, the healthcare analytics firm IQVIA was describing the approval as a watershed moment for the liver disease field, noting it was only the second MASH-specific therapy ever approved and the first from the GLP-1 class. That framing captures the real significance here: Wegovy isn’t just another weight-loss drug picking up a new use — it’s now one of exactly two approved options for a disease that affects millions of Americans and previously had none.
Who Actually Qualifies
The approval is narrower than “anyone with fatty liver.” It covers adults with non-cirrhotic MASH and moderate-to-advanced fibrosis — stage F2 or F3 on the NASH-CRN scale — confirmed generally through biopsy or increasingly through non-invasive scoring tools. Patients with early-stage simple fatty liver (no significant fibrosis) or those who have already progressed to cirrhosis are outside this specific indication, though semaglutide’s other approvals for obesity and cardiovascular risk reduction may still be relevant for those patients through a different clinical pathway.
Frequently Asked Questions
Is this a new drug or the same Wegovy used for weight loss?
Same drug, same 2.4 mg dose already approved for chronic weight management — just a new, FDA-cleared use for a specific liver condition. Semaglutide now carries obesity, cardiovascular risk reduction, and MASH indications simultaneously, which is unusual for any single drug.
Does this mean MASH is cured with Wegovy?
No. The trial data shows resolution of active liver inflammation and, in many patients, improvement in fibrosis — but MASH is a chronic, progressive condition, and long-term outcome data (fewer cirrhosis cases, transplants, and liver deaths) is still being collected in the ongoing ESSENCE Part 2 trial.
How is MASH diagnosed?
Historically through liver biopsy, though non-invasive tools like elastography and blood-based fibrosis scores are increasingly used to identify candidates before committing to an invasive procedure. If you’re trying to understand the broader landscape of GLP-1 indications, our comparison of Ozempic and Wegovy dosing covers how the same molecule gets used differently across approved indications.
Is this related to the recent Wegovy HD approval?
They’re separate developments on the same drug family. Wegovy HD (7.2 mg) is a higher weight-management dose approved in March 2026; the MASH indication uses the standard 2.4 mg dose for a completely different disease target. See our coverage of the Wegovy HD approval and STEP UP trial data for the weight-loss side of the story.
The Bigger Picture
A year in, the Wegovy MASH approval looks less like a marketing footnote and more like a genuine expansion of what GLP-1 drugs are for. Liver disease specialists now have clinical guidance to work from, a real (if still developing) evidence base, and a drug that many of their patients are already taking for weight or cardiovascular reasons. The open question isn’t whether semaglutide works for MASH — the histologic data says it does — it’s whether that benefit holds up over years, not months, once Part 2 of ESSENCE reports back.
This article is for educational purposes only and summarizes publicly available FDA, clinical trial, and professional society information. It is not medical advice. MASH is a serious liver condition that requires diagnosis and management by a qualified healthcare provider — talk to your doctor if you have risk factors for fatty liver disease.